Leukaemias are orphan diseases with a significant unmet medical need, applicable indications representing a growing market worth more than $5 billion by 2020
Nordic Nanovector has entered into a collaboration with Heidelberg Pharma GmbH, a subsidiary of biopharmaceutical company WILEX AG — specialising in the development of antibody-drug conjugates (ADCs) — to develop novel ADCs to treat leukaemias.
This collaboration is part of Nordic Nanovector’s strategy to develop its pipeline of targeted therapies to include antibody products conjugated to anticancer compounds that are not radionuclides. Such conjugates are commonly referred to as ADCs.
Jostein Dahle, Nordic Nanovector’s Chief Scientific Officer, commented: 'We are pleased to further expand our R&D activities into the ADC area with Heidelberg Pharma in this second strategic collaboration, following closely the collaboration announced recently with LegoChem.'
'During the past year, we have made important steps to execute our strategy designed to build a pipeline of innovative antibody-radionuclide conjugates (ARCs) and ADCs that combine our expertise and platform with complementary technologies from expert partners. This strategy is aimed at creating multiple new targeted treatment options for patients who suffer a range of leukaemias and lymphomas.'
Professor Dr Andreas Pahl, Head of Research and Development and member of the Management Board of WILEX and Heidelberg Pharma, commented: 'This project extends our portfolio of ADCs to further haematological cancers. Nordic Nanovector has an established chemistry, manufacturing and controls (CMC) process for their antibody, which will speed up processes and reduce the development costs of an ADC.'